Format

Send to

Choose Destination
Arthritis Rheum. 1994 Jul;37(7):992-9.

Treatment of refractory rheumatoid arthritis with a monoclonal antibody to intercellular adhesion molecule 1.

Author information

1
University of Texas Southwestern Medical Center, Dallas 75235-8884.

Abstract

OBJECTIVE:

To assess the safety and efficacy of a monoclonal antibody (MAb) to intercellular adhesion molecule 1 (ICAM-1; CD54) in rheumatoid arthritis (RA).

METHODS:

A phase I/II, open-label, dose-escalation study of 32 patients.

RESULTS:

During treatment, a peripheral CD3+/CD4+ lymphocytosis was noted, and several patients demonstrated transient cutaneous anergy, which suggests that therapy modified T cell recirculation. Thirteen of the 23 patients who received 5 days of treatment demonstrated clinical improvement through day 29, and 9 of 23 through day 60. Adverse effects were minor and transient.

CONCLUSION:

Anti-ICAM-1 MAb therapy was well tolerated, resulted in a transient alteration in T lymphocyte recirculation, and effected clinical improvement in some RA patients.

PMID:
7912930
DOI:
10.1002/art.1780370703
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center